Summary of Refrigerant Industry Conference Call Industry Overview - The refrigerant industry in China is experiencing stable quota policies, with the total quota for 2026 remaining the same as in 2025, while quotas for R25 and R41 are increased to compensate for the exit of 141B from the market, leading to an expected continuous rise in overall prices [1][3][18]. Key Points and Arguments Quota Adjustments and Price Trends - The quota for 232 types of refrigerants can be flexibly adjusted between 10% and 30%, allowing companies to respond to market demand while maintaining overall price increases under national control [1][4]. - The average price of third-generation refrigerants is approximately 50,000 yuan, with a long-term stable upward trend, although short-term volatility is expected for products like R32 [1][6]. Demand from Downstream Sectors - Despite a downturn in the global real estate market, demand for refrigerants in downstream sectors such as air conditioning and refrigeration continues to grow, with annual growth in new air conditioning units projected at 8% to 15% [1][7][12]. - Approximately 80% of new air conditioning units still utilize third-generation refrigerants, indicating a stable demand growth in the air conditioning market [8][12]. Future Production Capacity - An estimated 100,000 tons of new production capacity is expected to be launched in the Middle East and India by 2026, which could alleviate supply-demand tensions, although the success rate of these projects is anticipated to be below 40% [1][9][11]. Liquid Cooling Technology Impact - Liquid cooling technology is significantly increasing the demand for third-generation refrigerants, particularly in the semiconductor industry, with expected annual demand reaching tens of thousands of tons [1][14]. Second and Fourth Generation Refrigerants - The second-generation refrigerants are facing quota reductions, while the fourth-generation refrigerants currently lack formal domestic production capacity, with large-scale production expected only after 2030 [2][15]. - The price of second-generation refrigerants is expected to stabilize, while fourth-generation refrigerants are projected to see a rapid increase in application in air conditioning systems, reaching 20% by 2025 [20][21]. Additional Important Insights - The actual usage of refrigerants globally is around 23,000 tons, with a mismatch between planned production capacity and actual demand [17]. - The overall price trend for refrigerants is expected to maintain a 30% increase before 2029, driven by technological advancements and market demand changes [25]. - The current average price for second and third-generation refrigerants is about 80,000 yuan per ton, nearing a peak, with a potential ceiling at 100,000 yuan [23][24]. This summary encapsulates the key insights from the refrigerant industry conference call, highlighting the current state, future expectations, and underlying dynamics affecting the market.

Summary of Conference Call Records Company and Industry Overview - **Company**: 中华蓝天 (Zhonghua Lantian) and 昊华科技 (Haohua Technology) - **Industry**: Refrigerants, Lithium Battery Electrolytes, Civil Aviation Tires, Specialty Coatings, Carbon Reduction Technologies Key Points and Arguments Refrigerants Market - Zhonghua Lantian's refrigerant business benefits from quota policies and strong downstream demand, especially in the export market, with expectations for the market to remain at high levels despite potential price fluctuations due to policy changes [2][5] - Prices for products like 134a and 32 continue to rise, indicating a robust market environment [2][5] Liquid Cooling Technology - Zhonghua Lantian is actively developing liquid cooling technology for data centers, with products like YL-1-10 and YL-70 designed for silent liquid cooling applications [2][6] - The company has identified 134a as suitable for data center cooling plates and has begun limited sales, indicating a proactive approach to meet growing cooling demands [2][6] Electrolyte Research and Development - Zhonghua Lantian has invested in solid and semi-solid electrolyte research, boasting a production capacity of 250,000 tons and establishing a research institute for sulfide research [2][7] Civil Aviation Tires - The company has achieved significant milestones in civil aviation tires, obtaining airworthiness certificates for various aircraft models and beginning large-scale production [2][10] - Anticipated explosive growth in market supply by the end of 2025 or early 2026 due to successful trials and partnerships with major airlines [2][10][13] Specialty Coatings - Zhonghua Lantian's specialty coatings focus on functional coatings for civil aviation, shipping, and industrial applications, emphasizing high value and customization [2][14] - The company is targeting marine coatings as a key area for future breakthroughs [2][16] Carbon Reduction Business - The carbon reduction segment is benefiting from previous strategic investments, with significant orders nearing 4 billion yuan and a strong market outlook [2][18][19] - The company is recognized for its advanced gas separation technologies and is positioned as a leading provider in the carbon reduction field [2][18] Financial Performance - Haohua Technology reported a sales revenue of 7.76 billion yuan in the first half of 2025, a year-on-year increase of 19.45%, with net profit rising by 20.85% to 645 million yuan [3][4] - The fluorochemical segment saw a revenue increase of 24.99% and a gross profit increase of 40.73%, indicating strong performance across various business units [3][4] Market Dynamics in Lithium Battery Industry - The lithium battery industry is experiencing intense competition and overcapacity, leading to a challenging market environment [2][8][9] - The electrolyte and lithium additive sectors are currently in a downturn, with prices significantly lower than previous highs, necessitating a focus on technological advancements for competitive advantage [2][9] Future Outlook - Haohua Technology aims to become a leading enterprise in the gas sector, focusing on capacity expansion, technological development, and market exploration [2][24] - The company is set to complete a new production line for trifluorine nitrogen by the end of September 2025, which is expected to enhance profitability in the southwest region [2][22][23] Additional Important Insights - The civil aviation tire market is dominated by a few major players, but Zhonghua Lantian has positioned itself as a competitive fourth player with significant production capabilities [2][10] - The specialty coatings business is expected to grow due to increasing demand in various sectors, including renewable energy projects [2][15][16]

Financial Data and Key Metrics Changes - The company ended Q1 2025 with cash and cash equivalents of $13.9 million, down from $23.3 million as of December 31, 2024, indicating a significant decrease in liquidity [8] - Research and development expenses for Q1 2025 were approximately $3.4 million, a decrease from approximately $7.1 million in Q1 2024, primarily due to reduced patient follow-up activities and personnel costs [9] - General and administrative expenses for Q1 2025 were $3 million, down from $4.9 million in the same period in 2024, driven by reductions in pre-commercialization and personnel costs [9] - The net loss for Q1 2025 was $6.6 million, or $0.14 per share, compared to a net loss of $26.6 million, or $0.91 per share, in Q1 2024, reflecting a substantial improvement in financial performance [9] Business Line Data and Key Metrics Changes - The company is focusing on its PDC platform and radio conjugate pipeline, particularly the iapoficine I-131 for treating Waldenstrom's macroglobulinemia, which has shown promising efficacy and safety in clinical trials [5][6] - The company is also advancing its solid tumor-focused radioisotope programs, including treatments for pancreatic cancer and triple-negative breast cancer [6] Market Data and Key Metrics Changes - The company is seeking guidance from the EMA for conditional approval of iapoficine I-131 based on the results from the Phase II CLOVER WM clinical trial, which supports a rapid market entry for this treatment in Europe [5][6] - The management believes that the European market presents a significant opportunity, especially given the high utilization of rituximab in the region [42] Company Strategy and Development Direction - The company has engaged Oppenheimer as an exclusive financial advisor to explore strategic alternatives, including mergers, acquisitions, partnerships, and licensing arrangements [7] - The management is committed to advancing its clinical development pipeline and addressing the unmet medical needs in the relapsed-refractory market [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory pathway for iapoficine I-131, highlighting the strong data supporting its efficacy and safety [5][6] - The management noted the high unmet medical need in the patient population, particularly for those who have failed previous treatments [33] Other Important Information - The company is preparing for Phase I and Phase Ib studies for its earlier-stage radio conjugates, CLR121225 and CLR121.125, which are expected to provide valuable insights into their therapeutic potential [13][15] - The timeline for conditional approval from the EMA is anticipated in the third quarter of 2026, with a subsequent filing expected to take approximately twelve months for review [43] Q&A Session Summary Question: Regarding the application for conditional approval in Europe - The management discussed the potential for iapoficine I-131 to compete against rituximab in earlier lines of therapy, noting the challenges and costs associated with larger study sizes [19][22] Question: What is the weakest competitor arm for the Phase III trial? - Management indicated that there is little data available for many treatments in the NCCN guidelines, and they are focused on demonstrating the efficacy of iapoficine I-131 against existing therapies [25][29] Question: How does the company assess the commercial opportunity in Europe? - The management believes that the European market is rich, with a high utilization of rituximab, and that demonstrating superiority in clinical trials could enhance market positioning despite lower pricing [36][42]